Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $117.90M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.09M
Average 0.07M
ARMP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Armata Pharmaceuticals, Inc.AMEX: ARMP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $115.35M (cash outflow) rose 1666.1% year over year, behind the +66241.3% change in trailing-twelve-month net income. Sequentially, it fell 7.2% from the prior quarter. Over 3 fiscal years it compounded at +67.6% a year.
Context
- Net income amounted to 3544.0% of revenue in FY2025, up 3178.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$28.99M (-83.3%) for the fiscal year ending Dec 2026, a slowdown from the +818.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$115.35M-7.2% QoQ
- Last fiscal yearDec 2025
- -$173.8M+818.8% YoY
- LTMMar 2026
- -$282.61M+66241.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (173.8M) USD
- Year-over-year change
- -818.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (173.8M) | -818.8% |
| FY2024 | 2024-12-31 | (18.92M) | +72.6% |
| FY2023 | 2023-12-31 | (69.05M) | -87.0% |
| FY2022 | 2022-12-31 | (36.92M) | -59.4% |
| FY2021 | 2021-12-31 | (23.16M) | — |
Net Income vs competitors
How ARMP compares with its peers on the latest reported figures
- ARMP's LTM Mar 2026 net income of $282.61M is the largest of the 2 companies compared; the peer median is $15.24M.
- Its year-over-year change of +66241.3% is the highest of 2, against a peer median of +121.8%.
- Net income amounts to 9554.2% of revenue for ARMP, versus a peer median of 27.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $282.61M | +66241.3% | +67.6% | 9554.2% | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| Peer median (excluding ARMP) | $15.24M | +121.8% | — | 27.8% | |
Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Depreciation & Amortization | 1.17M | 892K | 972K | 1.33M | 1.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.88M | 3.11M | 938K | 2.89M | 2.61M |
| Change in Working Capital | (3.22M) | 439K | (9.65M) | (2.1M) | (1.41M) |
| Accounts Receivables | (2.43M) | 1.05M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 184K | 3.67M | 39K | (3.76M) | (334K) |
| Other Working Capital | (979K) | (4.28M) | (9.69M) | 1.66M | (1.08M) |
| Other Non-Cash Items | (1.25M) | 0 | 29.36M | (20.75M) | 145.31M |
| Operating Cash Flow | (23.58M) | (32.48M) | (47.42M) | (37.55M) | (25.76M) |
| Capital Expenditures | (1.3M) | (2.21M) | (8.14M) | (1.88M) | (542K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 10K | 0 | 0 |
| Investing Cash Flow | (1.3M) | (2.21M) | (8.13M) | (1.88M) | (542K) |
| Debt Repayment | 0 | 0 | 54.03M | 34.89M | 25M |
| Common Stock Issued | 26.32M | 44.52M | 5K | 130K | 658K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (801K) | (500K) | (43K) | (61K) | (46K) |
| Financing Cash Flow | 25.52M | 44.02M | 53.99M | 34.96M | 25.61M |
| Effect of Forex Changes | 0 | (4.76M) | 0 | 0 | 0 |
| Net Change in Cash | 639K | 4.56M | (1.57M) | (4.47M) | (693K) |
| Free Cash Flow | (24.88M) | (34.69M) | (55.57M) | (39.43M) | (26.31M) |
Armata Pharmaceuticals, Inc.
AMEX:ARMP
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.